Skip to main content
Top
Published in: Endocrine 2/2015

01-06-2015 | Original Article

Activating autoantibodies to the β1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism

Authors: Allison Galloway, Hongliang Li, Megan Vanderlinde-Wood, Muneer Khan, Alexandria Benbrook, Campbell Liles, Caitlin Zillner, Veitla Rao, Madeleine W. Cunningham, Xichun Yu, David C. Kem

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

We have previously demonstrated that activating autoantibodies to β1-adrenergic receptor (β1AR) and M2 muscarinic receptor (M2R) facilitate atrial fibrillation (AF) in patients with Graves’ disease (GD). The objectives of this expanded study were to examine the prevalence of β1AR, β2AR, and M2R autoantibodies in hyperthyroidism subjects. Sera from 81 patients including 31 with GD and AF, 36 with GD and sinus rhythm, 9 with toxic multinodular goiter, 5 with subacute thyroiditis, and 10 control subjects were examined for these autoantibodies by ELISA. Sera from 20 ELISA-positive GD subjects, 10 with AF and 10 with sinus rhythm, were assayed for autoantibody bioactivity using cell-based bioassays. In patients with GD and AF, 45, 65, and 77 % were ELISA positive for β1AR, M2R, and β2AR autoantibodies, respectively. In patients with GD and sinus rhythm, 17, 39, and 75 % were ELISA positive for β1AR, M2R, and β2AR autoantibodies, respectively. β1AR and M2R autoantibodies were co-present in 39 % of patients with GD and AF compared to 14 % in GD with sinus rhythm (p = 0.026). Patients with toxic multinodular goiter or subacute thyroiditis had a low prevalence of autoantibodies. The mean β1AR and M2R autoantibody activity was elevated in both GD groups but higher in those with AF than those with sinus rhythm. β2AR autoantibody activity was also increased in both groups. In conclusion, β1AR, β2AR, and M2R autoantibodies were elevated in GD. β1AR and M2R autoantibodies appear to be related to concurrent AF, while β2AR autoantibodies were equally prevalent in those with a sinus tachycardia and those with AF.
Literature
2.
go back to reference C. Selmer, J.B. Olesen, M.L. Hansen, J. Lindhardsen, A.M. Olsen, J.C. Madsen, J. Faber, P.R. Hansen, O.D. Pedersen, C. Torp-Pedersen, G.H. Gislason, The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 345, e7895 (2012)CrossRefPubMedCentralPubMed C. Selmer, J.B. Olesen, M.L. Hansen, J. Lindhardsen, A.M. Olsen, J.C. Madsen, J. Faber, P.R. Hansen, O.D. Pedersen, C. Torp-Pedersen, G.H. Gislason, The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 345, e7895 (2012)CrossRefPubMedCentralPubMed
3.
go back to reference I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501–509 (2001)CrossRefPubMed I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501–509 (2001)CrossRefPubMed
5.
go back to reference C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach, P.W. Wilson, E.J. Benjamin, R.B. D’Agostino, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994)CrossRefPubMed C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach, P.W. Wilson, E.J. Benjamin, R.B. D’Agostino, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994)CrossRefPubMed
6.
go back to reference Y.C. Chen, S.A. Chen, Y.J. Chen, M.S. Chang, P. Chan, C.I. Lin, Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J. Am. Coll. Cardiol. 39, 366–372 (2002)CrossRefPubMed Y.C. Chen, S.A. Chen, Y.J. Chen, M.S. Chang, P. Chan, C.I. Lin, Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J. Am. Coll. Cardiol. 39, 366–372 (2002)CrossRefPubMed
7.
go back to reference S. Stavrakis, X. Yu, E. Patterson, S. Huang, S.R. Hamlett, L. Chalmers, R. Pappy, M.W. Cunningham, S.A. Morshed, T.F. Davies, R. Lazzara, D.C. Kem, Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves’ hyperthyroidism. J. Am. Coll. Cardiol. 54, 1309–1316 (2009)CrossRefPubMedCentralPubMed S. Stavrakis, X. Yu, E. Patterson, S. Huang, S.R. Hamlett, L. Chalmers, R. Pappy, M.W. Cunningham, S.A. Morshed, T.F. Davies, R. Lazzara, D.C. Kem, Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves’ hyperthyroidism. J. Am. Coll. Cardiol. 54, 1309–1316 (2009)CrossRefPubMedCentralPubMed
8.
go back to reference J. Perez-Schindler, A. Philp, J. Hernandez-Cascales, Pathophysiological relevance of the cardiac beta2-adrenergic receptor and its potential as a therapeutic target to improve cardiac function. Eur. J. Pharmacol. 698, 39–47 (2013)CrossRefPubMed J. Perez-Schindler, A. Philp, J. Hernandez-Cascales, Pathophysiological relevance of the cardiac beta2-adrenergic receptor and its potential as a therapeutic target to improve cardiac function. Eur. J. Pharmacol. 698, 39–47 (2013)CrossRefPubMed
9.
go back to reference P.A. Chiale, H.A. Garro, J. Schmidberg, R.A. Sanchez, R.S. Acunzo, M. Lago, G. Levy, M. Levin, Inappropriate sinus tachycardia may be related to an immunologic disorder involving cardiac beta andrenergic receptors. Heart Rhythm 3, 1182–1186 (2006)CrossRefPubMed P.A. Chiale, H.A. Garro, J. Schmidberg, R.A. Sanchez, R.S. Acunzo, M. Lago, G. Levy, M. Levin, Inappropriate sinus tachycardia may be related to an immunologic disorder involving cardiac beta andrenergic receptors. Heart Rhythm 3, 1182–1186 (2006)CrossRefPubMed
10.
11.
go back to reference H. Li, D.C. Kem, S. Reim, M. Khan, M. Vanderlinde-Wood, C. Zillner, D. Collier, C. Liles, M.A. Hill, M.W. Cunningham, C.E. Aston, X. Yu, Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. Hypertension 59, 402–408 (2012)CrossRefPubMedCentralPubMed H. Li, D.C. Kem, S. Reim, M. Khan, M. Vanderlinde-Wood, C. Zillner, D. Collier, C. Liles, M.A. Hill, M.W. Cunningham, C.E. Aston, X. Yu, Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. Hypertension 59, 402–408 (2012)CrossRefPubMedCentralPubMed
12.
go back to reference H. Li, X. Yu, C. Liles, M. Khan, M. Vanderlinde-Wood, A. Galloway, C. Zillner, A. Benbrook, S. Reim, D. Collier, M.A. Hill, S.R. Raj, L.E. Okamoto, M.W. Cunningham, C.E. Aston, D.C. Kem, Autoimmune basis for postural tachycardia syndrome. J. Am. Heart Assoc. 3, e000755 (2014)CrossRefPubMedCentralPubMed H. Li, X. Yu, C. Liles, M. Khan, M. Vanderlinde-Wood, A. Galloway, C. Zillner, A. Benbrook, S. Reim, D. Collier, M.A. Hill, S.R. Raj, L.E. Okamoto, M.W. Cunningham, C.E. Aston, D.C. Kem, Autoimmune basis for postural tachycardia syndrome. J. Am. Heart Assoc. 3, e000755 (2014)CrossRefPubMedCentralPubMed
14.
go back to reference B. Olshansky, Interrelationships between the autonomic nervous system and atrial fibrillation. Prog. Cardiovasc. Dis. 48, 57–78 (2005)CrossRefPubMed B. Olshansky, Interrelationships between the autonomic nervous system and atrial fibrillation. Prog. Cardiovasc. Dis. 48, 57–78 (2005)CrossRefPubMed
15.
go back to reference S.S. Po, B.J. Scherlag, W.S. Yamanashi, J. Edwards, J. Zhou, R. Wu, N. Geng, R. Lazzara, W.M. Jackman, Experimental model for paroxysmal atrial fibrillation arising at the pulmonary vein-atrial junctions. Heart Rhythm 3, 201–208 (2006)CrossRefPubMed S.S. Po, B.J. Scherlag, W.S. Yamanashi, J. Edwards, J. Zhou, R. Wu, N. Geng, R. Lazzara, W.M. Jackman, Experimental model for paroxysmal atrial fibrillation arising at the pulmonary vein-atrial junctions. Heart Rhythm 3, 201–208 (2006)CrossRefPubMed
16.
go back to reference E. Patterson, S.S. Po, B.J. Scherlag, R. Lazzara, Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2, 624–631 (2005)CrossRefPubMed E. Patterson, S.S. Po, B.J. Scherlag, R. Lazzara, Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2, 624–631 (2005)CrossRefPubMed
17.
go back to reference H. Li, B.J. Scherlag, D.C. Kem, C. Zillner, S. Male, S. Thirunavukkarasu, X. Shen, J.V. Pitha, M.W. Cunningham, R. Lazzara, X. Yu, Atrial tachycardia provoked in the presence of activating autoantibodies to beta2-adrenergic receptor in the rabbit. Heart Rhythm 10, 436–441 (2013)CrossRefPubMedCentralPubMed H. Li, B.J. Scherlag, D.C. Kem, C. Zillner, S. Male, S. Thirunavukkarasu, X. Shen, J.V. Pitha, M.W. Cunningham, R. Lazzara, X. Yu, Atrial tachycardia provoked in the presence of activating autoantibodies to beta2-adrenergic receptor in the rabbit. Heart Rhythm 10, 436–441 (2013)CrossRefPubMedCentralPubMed
18.
go back to reference H. Li, B.J. Scherlag, D.C. Kem, A. Benbrook, X. Shen, M.W. Cunningham, R. Lazzara, C.E. Aston, X. Yu, Inducible cardiac arrhythmias caused by enhanced beta1-adrenergic autoantibody expression in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 306, H422–H428 (2014)CrossRefPubMedCentralPubMed H. Li, B.J. Scherlag, D.C. Kem, A. Benbrook, X. Shen, M.W. Cunningham, R. Lazzara, C.E. Aston, X. Yu, Inducible cardiac arrhythmias caused by enhanced beta1-adrenergic autoantibody expression in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 306, H422–H428 (2014)CrossRefPubMedCentralPubMed
19.
go back to reference H. Li, B.J. Scherlag, D.C. Kem, C. Zillner, S. Male, S. Thirunavukkarasu, X. Shen, A. Benbrook, J.V. Pitha, R. Lazzara, X. Yu, The propensity for inducing atrial fibrillation: a comparative study on old versus young rabbits. J. Aging Res. 2014, 684918 (2014)CrossRefPubMedCentralPubMed H. Li, B.J. Scherlag, D.C. Kem, C. Zillner, S. Male, S. Thirunavukkarasu, X. Shen, A. Benbrook, J.V. Pitha, R. Lazzara, X. Yu, The propensity for inducing atrial fibrillation: a comparative study on old versus young rabbits. J. Aging Res. 2014, 684918 (2014)CrossRefPubMedCentralPubMed
20.
go back to reference H. Li, B.J. Scherlag, D.C. Kem, A. Benbrook, L. Zhang, B. Huang, M.W. Cunningham, R. Lazzara, X. Yu, Atrial tachyarrhythmias induced by the combined effects of beta1/2-adrenergic autoantibodies and thyroid hormone in the rabbit. J. Cardiovasc. Trans. Res. 7, 581–589 (2014)CrossRef H. Li, B.J. Scherlag, D.C. Kem, A. Benbrook, L. Zhang, B. Huang, M.W. Cunningham, R. Lazzara, X. Yu, Atrial tachyarrhythmias induced by the combined effects of beta1/2-adrenergic autoantibodies and thyroid hormone in the rabbit. J. Cardiovasc. Trans. Res. 7, 581–589 (2014)CrossRef
21.
go back to reference M.D. Rodefeld, S.L. Beau, R.B. Schuessler, J.P. Boineau, J.E. Saffitz, Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density. J. Cardiovasc. Electrophysiol. 7, 1039–1049 (1996)CrossRefPubMed M.D. Rodefeld, S.L. Beau, R.B. Schuessler, J.P. Boineau, J.E. Saffitz, Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density. J. Cardiovasc. Electrophysiol. 7, 1039–1049 (1996)CrossRefPubMed
Metadata
Title
Activating autoantibodies to the β1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism
Authors
Allison Galloway
Hongliang Li
Megan Vanderlinde-Wood
Muneer Khan
Alexandria Benbrook
Campbell Liles
Caitlin Zillner
Veitla Rao
Madeleine W. Cunningham
Xichun Yu
David C. Kem
Publication date
01-06-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0495-4

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine